Leukeran

Chlorambucil, the active ingredient in Leukeran, is a alkylating agent presented as a tablet for oral use. It is employed in the treatment of certain lymphoid cancers, including chronic lymphocytic leukemia and Hodgkin's lymphoma, in adult patients. GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leukeran is an alkylating antineoplastic agent indicated for malignancies of the lymphoid system.

- Chronic lymphocytic leukemia: helps achieve disease control and prolong survival. - Hodgkin's lymphoma: contributes to remission when used as part of combination chemotherapy. - Other lymphoid malignancies: provides therapeutic benefit in selected cases of non‑Hodgkin lymphoma and related disorders.

Leukeran may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Myelosuppression: decreased white blood cells, red blood cells, and platelets. - Alopecia: hair thinning or loss. - Fatigue: generalized tiredness. - Mucositis: inflammation of the mouth lining.

Serious or Rare Side Effects: - Severe infection: due to profound neutropenia. - Hemorrhage: from thrombocytopenia. - Secondary malignancies: increased risk of therapy‑related cancers. - Hepatotoxicity: liver enzyme elevations or dysfunction. - Pulmonary fibrosis: rare lung tissue scarring.

Before initiating Leukeran therapy, several safety considerations should be reviewed. - Baseline blood counts: assess hematologic status to monitor for myelosuppression. - Liver function: evaluate hepatic enzymes as the drug is metabolized hepatically. - Renal function: adjust use if significant impairment exists. - Infection risk: implement prophylactic measures and educate patients on signs of infection. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks. - Store at ambient temperature: keep below 25°C, in the original container, protected from moisture and direct sunlight.

Chlorambucil can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Live vaccines: increased risk of infection due to immunosuppression. - Strong CYP450 inducers (e.g., rifampin): may reduce chlorambucil plasma levels. - Anticoagulants (e.g., warfarin): heightened bleeding risk from thrombocytopenia.

Moderate Interactions (Monitor Closely): - Other myelosuppressive agents: additive bone‑marrow toxicity. - Allopurinol: may increase risk of hypersensitivity reactions. - NSAIDs: potential for renal impairment when combined with nephrotoxic agents.